用新型选择性5-羟色胺2（5-HT2）受体拮抗剂酮色林治疗高血压。
Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
作者信息
Wenting G J, Man in 't Veld A J, Woittiez A J, Boomsma F, Schalekamp M A
出版信息
Br Med J (Clin Res Ed). 1982 Feb 20;284(6315):537-9. doi: 10.1136/bmj.284.6315.537.
Abstract
The new selective 5-HT2 receptor blocking agent ketanserin was given in a dose of 10 mg intravenously to 12 patients with essential hypertension. It caused a distinct fall in supine systemic arterial, right atrial, pulmonary artery, and pulmonary capillary "wedge" pressures. Cardiac output, renal blood flow, and glomerular filtration rate showed no persistent changes. Thus 5-HT2 receptor blockade caused dilatation of both resistance and capacitance vessels and of the renal vascular bed. Heart rate and plasma concentrations of renin and noradrenaline rose after ketanserin. These data suggest that 5-HT may have a role in maintaining high blood pressure.
摘要
给12例原发性高血压患者静脉注射10毫克新型选择性5-羟色胺2（5-HT2）受体阻滞剂酮色林。它使仰卧位时的体循环动脉压、右心房压、肺动脉压和肺毛细血管“楔压”明显下降。心输出量、肾血流量和肾小球滤过率未显示持续变化。因此，5-HT2受体阻滞导致阻力血管、容量血管以及肾血管床扩张。注射酮色林后心率、肾素和去甲肾上腺素的血浆浓度升高。这些数据表明5-羟色胺可能在维持高血压中起作用。
相似文献
1
Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
Br Med J (Clin Res Ed). 1982 Feb 20;284(6315):537-9. doi: 10.1136/bmj.284.6315.537.
2
5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.
Hypertension. 1984 Jan-Feb;6(1):100-9. doi: 10.1161/01.hyp.6.1.100.
3
Ketanserin: a possible tool for studying the role of serotonin in hypertension.
J Cardiovasc Pharmacol. 1985;7 Suppl 7:S130-6.
4
Cardiovascular effects of ketanserin in the treatment of hypertension during coronary artery bypass surgery.
J Cardiovasc Pharmacol. 1986 Jan-Feb;8(1):109-15. doi: 10.1097/00005344-198601000-00017.
5
5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
Lancet. 1981 May 30;1(8231):1186-8. doi: 10.1016/s0140-6736(81)92352-7.
6
Controlled trial of ketanserin in hypertension.
Br J Clin Pharmacol. 1985 Jul;20(1):37-40. doi: 10.1111/j.1365-2125.1985.tb02795.x.
7
Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin.
J Cardiovasc Pharmacol. 1985;7 Suppl 7:S64-6. doi: 10.1097/00005344-198500077-00019.
8
Ketanserin, a serotonin antagonist. Administration in patients with acute respiratory failure.
Chest. 1984 Apr;85(4):510-3. doi: 10.1378/chest.85.4.510.
9
Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise.
J Hypertens. 1983 Dec;1(4):405-12. doi: 10.1097/00004872-198312000-00014.
引用本文的文献
1
Serotonin and blood pressure regulation.
Pharmacol Rev. 2012 Apr;64(2):359-88. doi: 10.1124/pr.111.004697. Epub 2012 Mar 8.
2
5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.
Cardiovasc Ther. 2011 Feb;29(1):54-67. doi: 10.1111/j.1755-5922.2010.00173.x.
3
Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
Br Med J (Clin Res Ed). 1982 Oct 16;285(6348):1069-71. doi: 10.1136/bmj.285.6348.1069.
4
Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
Br J Clin Pharmacol. 1984 Mar;17(3):309-16. doi: 10.1111/j.1365-2125.1984.tb02346.x.
5
Acute effects of ketanserin on left ventricular function, metabolism and coronary blood flow.
Br J Clin Pharmacol. 1984 Mar;17(3):301-7. doi: 10.1111/j.1365-2125.1984.tb02345.x.
6
Effects of LM 5008, a selective inhibitor of 5-hydroxytryptamine uptake, on blood pressure and responses to sympathomimetic amines.
Br J Pharmacol. 1983 Aug;79(4):915-22. doi: 10.1111/j.1476-5381.1983.tb10536.x.
7
Ketanserin in essential hypertension: effects during rest and exercise.
Eur J Clin Pharmacol. 1983;25(3):307-12. doi: 10.1007/BF01037939.
8
The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.
Br J Clin Pharmacol. 1983 Sep;16(3):305-11. doi: 10.1111/j.1365-2125.1983.tb02166.x.
9
Pharmacokinetics of ketanserin in man.
Eur J Clin Pharmacol. 1983;25(1):73-6. doi: 10.1007/BF00544018.
10
Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.
Br J Clin Pharmacol. 1983 Aug;16(2):121-5. doi: 10.1111/j.1365-2125.1983.tb04974.x.
本文引用的文献
1
Supersensitivity of atherosclerotic rabbit aorta to ergonovine. Mediation by a serotonergic mechanism.
J Clin Invest. 1980 Aug;66(2):306-13. doi: 10.1172/JCI109858.
2
Review of the role of the central serotonergic neuronal system in blood pressure regulation.
Hypertension. 1980 May-Jun;2(3):243-55. doi: 10.1161/01.hyp.2.3.243.
3
Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.
Life Sci. 1981 Mar 2;28(9):1015-22. doi: 10.1016/0024-3205(81)90747-5.
4
Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.
J Pharmacol Exp Ther. 1981 Jul;218(1):217-30.
5
5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
Lancet. 1981 May 30;1(8231):1186-8. doi: 10.1016/s0140-6736(81)92352-7.
6
Acute blood-pressure-lowering effect of ketanserin.
Lancet. 1981 May 23;1(8230):1161-2. doi: 10.1016/s0140-6736(81)92331-x.
7
Abnormal renal haemodynamics and renin suppression in hypertensive patients.
Clin Sci. 1970 Jan;38(1):101-10. doi: 10.1042/cs0380101.
8
A sensitive radioenzymatic assay for norepinephrine in tissues and plasma.
Life Sci. 1975 Feb 1;16(3):375-84. doi: 10.1016/0024-3205(75)90258-1.
9
Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol.
Mol Pharmacol. 1979 Nov;16(3):687-99.
10
Inactive renin in human plasma.
Lancet. 1976 Sep 4;1(7984):496-9. doi: 10.1016/s0140-6736(76)90791-1.
Zotero 插件